Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inwards

Showing results (311-320 of 382) with videos related to

Pageof 39
Sort By:
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
European Journal of Haematology|January 29, 2008
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAngela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, et al.
Blood Cancer Journal|April 30, 2021
Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysisNirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Leukemia|October 14, 2018
Primary systemic amyloidosis in patients with Waldenström macroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Blood Cancer Journal|December 5, 2019
Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysisNirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
The Journal of Surgical Research|July 30, 2025
Qualitative Analysis of Program Director Perspectives on Conscientious Objection Policies to Gender-Affirming CareRebecca Arteaga, Danielle J Eble, Alisha L Nguyen, et al.
Leukemia & Lymphoma|January 12, 2018
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphomaMohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Pageof 39

Showing results (311-320 of 382) with videos related to

Sort By:
Pageof 39
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
European Journal of Haematology|January 29, 2008
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAngela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, et al.
Blood Cancer Journal|April 30, 2021
Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysisNirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Leukemia|October 14, 2018
Primary systemic amyloidosis in patients with Waldenström macroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Blood Cancer Journal|December 5, 2019
Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysisNirav N Shah, Kwang Woo Ahn, Carlos Litovich, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
The Journal of Surgical Research|July 30, 2025
Qualitative Analysis of Program Director Perspectives on Conscientious Objection Policies to Gender-Affirming CareRebecca Arteaga, Danielle J Eble, Alisha L Nguyen, et al.
Leukemia & Lymphoma|January 12, 2018
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphomaMohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Pageof 39